To evaluate whether incorporating locoregional radiotherapy in the treatment of oligometastatic renal cell carcinoma, including inductive oligometastases, along with standard systemic therapy, contributes to improved progression-free survival rates for patients.
Patients with metastatic renal cell carcinoma classified within the ESTRO/EORTC classification system as having ≤ 5 metastases, ≤ 3 metastatic organs, and meeting criteria for new, recurrent, or induced metastases.
Patients aged 20 to 80 years.
Patients with individual metastases ≤ 5 cm in longest diameter.
Patients with primary tumors surgically removed or scheduled for surgery.
Patients with total bilirubin > 3.6 mg/dL.
Patients with AST >160 U/L, ALT > 165 U/L.
Patients unable to maintain position for partial nephrectomy radiotherapy.
Patients with a history of radiotherapy to metastatic renal cell carcinoma or surrounding areas.
Parallel
SBRT(Stereotatic Body Radiation Therapy)
RadiationPatients will receive treatment for one to two weeks, one to five times per region.
1-year progression-free survival rate
Compare free survival between the standard systemic therapy alone group and systemic therapy combined with radiotherapy group
Local control rate for radiation therapy site at one year
Compare Local control rate between the standard systemic therapy alone group and systemic therapy combined with radiotherapy group
Grade 3 acute adverse event
Compare acute adverse events according to CTCAE V5.0 between the standard systemic therapy alone group and systemic therapy combined with radiotherapy group
Grade 3 chronic adverse event
Compare chronic adverse events according to CTCAE V5.0 between the standard systemic therapy alone group and systemic therapy combined with radiotherapy group
Overall survival rate
Compare Overall survival rate between the standard systemic therapy alone group and systemic therapy combined with radiotherapy group
Click on the lead sponsor to view all of their trials.
